Prednisone pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers for "prednisone pharmacokinetics"
Prednisone Pharmacokinetics: Absorption, Metabolism, and Conversion
Prednisone is a prodrug that is rapidly converted in the liver to its active metabolite, prednisolone, after oral administration. This conversion occurs within 30 minutes in both humans and dogs, with prednisolone plasma concentrations typically 4- to 10-fold higher than prednisone concentrations following administration Rose1981Sebbag2020Cai2025. The interconversion between prednisone and prednisolone is dose- and time-dependent, and the ratio of prednisolone to prednisone remains relatively constant across dosing regimens, indicating non-saturation of the hepatic enzyme responsible for this conversion Rose1981Sebbag2020.
Dose-Dependent and Nonlinear Pharmacokinetics
The pharmacokinetics of prednisone and prednisolone are dose-dependent and nonlinear. As the dose increases, the plasma clearance of both drugs also increases, but not in a linear fashion. For example, oral prednisone plasma clearance in humans ranges from 572 ml/min/1.73 m² at a 5 mg dose to 2271 ml/min/1.73 m² at a 50 mg dose . Similarly, in pregnant women, apparent oral clearance of prednisone and renal clearance of prednisolone both increase with higher doses . This nonlinearity is largely attributed to the concentration-dependent binding of prednisolone to plasma proteins, particularly corticosteroid-binding globulin (CBG) and albumin Rose1981Xu2007Li2020+1 MORE.
Protein Binding and Distribution
Prednisolone exhibits nonlinear, concentration-dependent protein binding, which significantly influences its pharmacokinetics. As plasma concentrations rise, a higher percentage of the drug remains unbound, leading to increased clearance and distribution Rose1981Xu2007Li2020+1 MORE. The steady-state volume of distribution for prednisolone also increases with dose, but mean transit time and half-life show little change . In tissue distribution studies, prednisolone shows the highest binding in muscle and liver, with lower concentrations in fat, kidney, lung, and brain, the latter likely due to P-glycoprotein-mediated efflux .
Special Populations: Pregnancy, Lactation, and Transplant Recipients
During pregnancy, both prednisone and prednisolone show increased clearance and a higher fraction of unbound drug, but infant exposure through breast milk remains minimal . In renal transplant recipients, there is significant inter-individual variability in prednisolone exposure and suppression of endogenous cortisol, suggesting a potential role for therapeutic drug monitoring to optimize dosing . In pediatric kidney transplant patients, population pharmacokinetic models have been developed to predict free prednisolone concentrations and account for variability in drug exposure .
Food Effects and Bioavailability
Food intake delays the time to reach peak plasma concentrations (Tmax) of both prednisone and prednisolone by about 0.5 hours but does not affect the overall systemic exposure (AUC) . The bioavailability of prednisolone after oral prednisone is approximately 80% of that after direct prednisolone administration, and about 20% of prednisolone is converted back to prednisone after oral prednisolone dosing .
Clinical Implications and Dosing Considerations
The nonlinear and dose-dependent pharmacokinetics of prednisone and prednisolone, influenced by protein binding and metabolic interconversion, highlight the importance of individualized dosing, especially in populations with altered physiology such as pregnant women, transplant recipients, and pediatric patients Rose1981Xu2007Ryu2018+2 MORE. Monitoring free prednisolone concentrations and considering patient size and protein binding capacity can help avoid under- or over-dosage, improving therapeutic outcomes and minimizing toxicity Mangin2020De Truchis2022.
Conclusion
Prednisone pharmacokinetics are complex, involving rapid hepatic conversion to prednisolone, dose- and concentration-dependent clearance, and nonlinear protein binding. These factors contribute to significant variability in drug exposure, necessitating careful consideration of dosing strategies and, in some cases, therapeutic drug monitoring to ensure safe and effective treatment.
Sources and full results
Most relevant research papers on this topic